Filing Summary
Business Context and Reporting Period
This Form 8-K was filed by Vallon Pharmaceuticals, Inc. on June 9, 2022, regarding matters submitted at its Annual Meeting of Stockholders held that day. The provided metadata identifies GRI Bio, Inc., but the filing registrant is Vallon Pharmaceuticals, Inc. The filing does not report quarterly or annual financial results.
Annual Meeting and Voting Results
- As of the April 14, 2022 record date, 6,812,836 shares were outstanding and entitled to vote.
- 3,823,241 shares, approximately 56% of those entitled to vote, were present in person or by proxy, constituting a quorum.
- David Baker was elected as a Class I director for the remaining two years of the class term.
- Richard Ammer and Marella Thorell were elected as Class II directors serving until the 2025 Annual Meeting.
- Joseph Payne and Meenu Karson continued as Class III directors until the 2023 Annual Meeting.
- Stockholders ratified EisnerAmper LLP as the independent registered public accounting firm for the year ending December 31, 2022, with 3,816,732 votes for, 4,246 against, and 2,263 abstentions.
- Stockholders approved, on a non-binding advisory basis, the 2021 compensation of named executive officers, with 2,565,895 votes for, 36,795 against, 7,405 abstentions, and 1,213,146 broker non-votes.
- Stockholders approved annual advisory votes on executive compensation, with 2,594,279 votes for one-year frequency, compared with 4,161 for two years and 3,436 for three years.
Financial Metrics and Material Changes
The filing text does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, or operating performance metrics. It does not disclose a material change in financial condition versus a prior comparable period.
Outlook, Risks, and Unusual Items
The filing contains no management outlook, forward guidance, material risk update, contingency, or unusual financial item. The principal disclosed matters are director elections, auditor ratification, executive compensation approval, and the selected annual frequency of future advisory compensation votes.
Investor Verification Items
- Verify the registrant identity, because the filing names Vallon Pharmaceuticals, Inc., while the request metadata names GRI Bio, Inc.
- Confirm the elected directors’ class assignments and term lengths.
- Confirm EisnerAmper LLP’s appointment for the year ending December 31, 2022.
- Review subsequent filings for any corporate name change, merger, or other development that may explain the metadata discrepancy.